Objective: Success rates of amoxicillin, clarithromycin, and proton-pump inhibitor therapy in the Helicobacter pylori (Hp) eradication have been decreasing. The aim of this study was to investigate the impact of bismuth subcitrate ad-dition to triple therapy. Materials and methods: 148 patients diagnosed Hp infection with both histology and Hp stool antigen (HpSA) tests were examined retrospectively. The patients were divided into 3 groups according to the eradication therapy. The first group received triple therapy with claritromycine 2x 500 mg, amoxicilline 2x1 g and PPI 2x1 for 14 days (n=40). The second group had bismuth subcitrate 4x120 mg with triple therapy for 14 days (n=73). The third group received 14 days pretreatment with bismuth subcitrate 4x1 together with PPI 2x1 then had triple therapy for 14 days (n=35). (14)C urea breath and HpSA tests were used to detect posttreatment H.pylori status. Results: There were no statistical difference between the groups in terms of gender and age (p > 0.05). In group one 12 patients, in group two 20 patients and in group three 10 patients were identified as Hp positive after treatment. Eradication rates were 70% for group one, 72.6% for group two and 71.4% for group three respectively. There was no statistical difference between the groups in terms of eradication rates of treatment (p > 0.05). Conclusions: The addition of bismuth to conventional triple therapy did not affect treatment success rates.
Alan : Sağlık Bilimleri
Dergi Türü : Uluslararası
Benzer Makaleler | Yazar | # |
---|
Makale | Yazar | # |
---|